An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Hepatology International, Journal Year: 2023, Volume and Issue: 17(4), P. 773 - 791

Published: May 19, 2023

Language: Английский

---

An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease

Med, Journal Year: 2024, Volume and Issue: 5(7), P. 797 - 815.e2

Published: April 26, 2024

Language: Английский

---

Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions

Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2220 - 2220

Published: July 11, 2024

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.

Language: Английский

---

Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: April 16, 2024

Background Non-alcoholic fatty liver disease (NAFLD) is a common chronic disease, affecting 25-30% of the general population globally. The condition even more prevalent in individuals with obesity and frequently linked to metabolic syndrome. Given known associations between syndrome mental health issues, it likely that such relationship also exists NAFLD problems. However, studies this field remain limited. Accordingly, aim systematic review meta-analysis was explore prevalence one or conditions (i.e., depression, anxiety, and/or stress) adults NAFLD. Methods PubMed, EBSCOhost, ProQuest, Ovid, Web Science, Scopus were searched order identify reporting stress among A random-effects model utilized calculate pooled confidence intervals for anxiety stress. Results In total, 31 eligible inclusion, involving 2,126,593 Meta-analyses yielded 26.3% (95% CI: 19.2 34) 37.2% 21.6 54.3%) 51.4% 5.5 95.8%) Conclusion present findings suggest high morbidity related public impact, finding should prompt further research investigate elucidate potential morbidity, exploring shared underlying pathophysiologic mechanisms. Systematic registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42021288934.

Language: Английский

---

The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(2), P. 428 - 428

Published: Jan. 10, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern, and it not only the keystone precursor of eventual liver-related morbidity, but also places patients at considerably higher cardiovascular risk, which still a leading cause death in these patients. The most important common underlying pathophysiological mechanisms diseases are primarily related to insulin resistance, chronic inflammation oxidative stress. presence MASLD with (CVD) type 2 diabetes mellitus (T2DM) elevates risk for poor outcomes, thus this review highlights method therapeutic approaches. Given intertwined nature MASLD, T2DM, CVD, there urgent need strategies that address all three conditions. Although lifestyle changes as treatment, medication plays crucial role managing hyperglycemia, enhancing function lowering risk. onset progression should be addressed through multifaceted approach, targeting inflammatory, immune, metabolic, stress, hormonal gutaxis pathways, alongside treatment T2DM. In review, we discuss effects antidiabetic drugs impact on both outcomes affected by T2DM CDV.

Language: Английский

---

An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: Jan. 28, 2025

Language: Английский

---

Lipid Biomarkers and Cardiometabolic Diseases: Critical Knowledge Gaps and Future Research Directions

Metabolites, Journal Year: 2025, Volume and Issue: 15(2), P. 108 - 108

Published: Feb. 7, 2025

The past decade has witnessed transformative changes in our understanding of various lipid or lipid-related biomarkers (Table 1) and their relationships with cardiometabolic diseases [...].

Language: Английский

---

A personalized approach to the treatment of patients with chronic heart failure with preserved ejection fraction and non-alcoholic fatty liver disease using dapagliflozin

Experimental and Clinical Gastroenterology, Journal Year: 2025, Volume and Issue: 9, P. 14 - 25

Published: March 6, 2025

Language: Английский

---

Non-Alcoholic Fatty Liver Disease and Its Progression: Impact of Metabolic Syndrome and Future Treatment Strategies

Indus journal of bioscience research., Journal Year: 2025, Volume and Issue: 3(3), P. 146 - 152

Published: March 16, 2025

NAFLD has emerged as a significant global health problem since it impacts around 25 percent of people and strongly associates with metabolic syndrome. The development from simple hepatic steatosis through non-alcoholic steatohepatitis (NASH) eventually leads to fibrosis cirrhosis hepatocellular carcinoma. rising prevalence parallels the obesity epidemic, type 2 diabetes mellitus, insulin resistance, dyslipidemia, hypertension serving key risk factors. causes serious systemic problems beyond liver complications because substantially raises probabilities developing cardiovascular disease chronic kidney ischemic stroke. Diagnosing accurately remains difficult biopsy provides most reliable results while remaining invasive unsuitable for widespread use. Investigators search non-invasive diagnostic methods such serum biomarker evaluation imaging techniques but these approaches still struggle differentiate fatty damage advancing NASH. an increasing burden without any pharmacological treatment options approved by FDA. Weight loss achieved diet exercise stands primary element treatment. Novel drugs GLP-1 receptor agonists SGLT-2 inhibitors FXR have demonstrated capacity reduce development. research compiles existing peer-reviewed studies that explain syndrome–NAFLD progression relationships explores therapeutic developments NAFLD. This review seeks improve early detection presenting guidance about management clinical professionals researchers policy-making experts. growing together its consequences requires multidisciplinary model which merges care hepatologic both patient results.

Language: Английский

---

Hepatokine and Proinflammatory Cytokine Profile in Patients with Carotid Atherosclerosis and Metabolic Dysfunction-Associated Steatotic Liver Disease

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 978 - 978

Published: April 16, 2025

Background and Aims: Hepatokines have a regulatory function in adipose tissue inflammation, metabolic dysfunction-associated steatotic liver disease (MASLD), cardiovascular diseases, atherosclerosis. Our aim was to evaluate the profile of proinflammatory cytokines hepatokines patients with MASLD carotid atherosclerosis (CA). Methods: A prospective basic research study conducted on MASLD. Clinical data were collected from detailed medical history. Liver stiffness measured using transient elastography, Doppler ultrasound performed. Levels biochemical parameters, systemic inflammation markers (TNF-α, IL-6, IL-10, IL-18), (FGF21, ANGPTL4, fetuin-A) determined. The results analyzed SPSS v22.0 software. Results: Sixty-seven included, 72.1% women, mean patient age 53.9 + 11.3 years. Atherosclerosis found 11 (16.2%), intima–media thickness (CIMT) altered right 13 (19.1%), left 19 (27.9%), bilaterally 7 (10.3%). Greater (p = 0.001) high blood pressure 0.028) correlated There no differences markers, FGF21 fetuin-A tended increase presence CIMT CA alterations, regardless fibrosis. Conclusions: In our population, had 16.6% prevalence CA, risk increased history pressure. atherosclerosis, suggesting that combination these could guide us suspect early endothelial alterations

Language: Английский

---